Trastuzumab deruxtecan

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Brain Cancer

Conditions

Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma

Trial Timeline

Sep 22, 2023 → Sep 22, 2027

NCT ID

NCT06058988

About Trastuzumab deruxtecan

Trastuzumab deruxtecan is a phase 2 stage product being developed by AstraZeneca for Brain Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06058988. Target conditions include Brain Cancer, Glioblastoma, Metastatic Cancer.

What happened to similar drugs?

5 of 18 similar drugs in Brain Cancer were approved

Approved (5) Terminated (2) Active (13)

✅ExenatideAstraZenecaApproved

✅RivastigmineNovartisApproved

✅Genotropin (PN-180,307) SomatropinPfizerApproved

✅Genotropin + PlaceboPfizerApproved

✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved

🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07428044	Phase 2	Recruiting	Feb 13, 2026	Feb 13, 2027	Non-Small Cell Lung Cancer
NCT07124000	Pre-clinical	Recruiting	Sep 18, 2025	Mar 30, 2028	Adenocarcinoma (NOS)
NCT06727227	Pre-clinical	Recruiting	Jan 29, 2025	Oct 31, 2027	Breast Cancer
NCT06429761	Approved	Recruiting	Jan 2, 2025	Oct 31, 2026	BREAST CANCER
NCT05965479	Phase 2	Recruiting	Apr 10, 2024	Apr 30, 2028	Gastrooesophageal Cancer
NCT06231693	Pre-clinical	Terminated	Dec 4, 2023	Mar 26, 2024	Breast Cancer
NCT05744375	Phase 2	Terminated	Sep 28, 2023	Jul 17, 2025	Locally Advanced Breast Cancer
NCT06058988	Phase 2	Recruiting	Sep 22, 2023	Sep 22, 2027	Brain Cancer

Competing Products

20 competing products in Brain Cancer

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	39
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
Pembrolizumab + Lenvatinib	Eisai	Phase 2	42
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	27
GLIADEL	Eisai	Phase 2	35
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	29
abemaciclib + abemaciclib	Eli Lilly	Phase 2	39
JNJ-17299425	Johnson & Johnson	Phase 2	27
ABT-888	AbbVie	Phase 1	29
Veliparib + Placebo	AbbVie	Phase 2	35
Iressa (Gefitinib)	AstraZeneca	Phase 2	27
Exenatide	AstraZeneca	Approved	43
AZD5213	AstraZeneca	Phase 1	29
Vorinostat	Merck	Phase 1	29